# Globus Medical Inc. (GMED)

**Exchange:** NYSE  
**Sector:** Healthcare  
**Market cap:** $11.08B  
**Price:** $80.86 (-2.01%)

> Globus Medical Inc. is a leading global musculoskeletal technology company that develops and commercializes implantable devices, biologics, accessories, and surgical instruments for spinal, orthopedic trauma, neurosurgical, and joint reconstruction procedures. The company focuses on solving unmet clinical needs through innovative solutions, including its comprehensive spine and orthopedic portfolios, regenerative biologics, and enabling technologies such as robotics, navigation systems, and the Excelsius™ platform. Globus Medical provides world-class education and clinical support via its Musculoskeletal Education and Research Center, offering training in cadaveric labs, research facilities with biomechanical testing, and peer-to-peer programs to advance patient outcomes. It emphasizes exceptional surgeon response, rapid product innovation through iterative design cycles, and collaboration with healthcare professionals to enhance surgical accuracy, minimize invasiveness, and improve care efficiency. Founded in 2003 and headquartered in Audubon, Pennsylvania, Globus Medical plays a vital role in the medical device industry by delivering technologies that promote healing for patients with musculoskeletal disorders.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $2.94B | $1.98B | $480M | $538M | $3.92 |
| 2024 | $2.52B | $1.48B | $166M | $103M | $0.75 |
| 2023 | $1.57B | $1.02B | $133M | $123M | $1.07 |
| 2022 | $1.02B | $759M | $228M | $190M | $1.85 |
| 2021 | $958M | $719M | $172M | $149M | $1.44 |
| 2020 | $789M | $572M | $111M | $102M | $1.01 |
| 2019 | $785M | $605M | $172M | $155M | $1.52 |
| 2018 | $713M | $554M | $169M | $156M | $1.54 |
| 2017 | $636M | $486M | $162M | $107M | $1.10 |
| 2016 | $564M | $429M | $154M | $104M | $1.08 |
| 2015 | $545M | $412M | $172M | $113M | $1.17 |
| 2014 | $474M | $364M | $138M | $92M | $0.97 |
| 2013 | $434M | $334M | $102M | $69M | $0.73 |
| 2012 | $386M | $311M | $115M | $74M | $0.80 |
| 2011 | $331M | $263M | $97M | $61M | $0.67 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $5.30B | $730M | $4.57B | $526M | — |
| 2024 | $5.25B | $1.07B | $4.18B | $784M | — |
| 2023 | $5.09B | $1.09B | $4.00B | — | — |
| 2022 | $2.08B | $230M | $1.85B | — | — |
| 2021 | $1.96B | $216M | $1.74B | — | — |
| 2020 | $1.68B | $173M | $1.51B | — | — |
| 2019 | $1.53B | $130M | $1.40B | $195M | — |
| 2018 | $1.30B | $115M | $1.19B | $140M | — |
| 2017 | $1.08B | $111M | $968M | $119M | — |
| 2016 | $928M | $96M | $832M | $67M | — |
| 2015 | $834M | $119M | $715M | $58M | — |
| 2014 | $704M | $118M | $585M | $82M | — |
| 2013 | $566M | $94M | $472M | $90M | — |
| 2012 | $447M | $61M | $387M | $212M | — |
| 2011 | $329M | $47M | $282M | $143M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $753M | $165M | $589M |
| 2024 | $521M | $115M | $405M |
| 2023 | $243M | $78M | $165M |
| 2022 | $178M | $74M | $104M |
| 2021 | $276M | $57M | $219M |
| 2020 | $199M | $64M | $135M |
| 2019 | $172M | $71M | $101M |
| 2018 | $182M | $60M | $122M |
| 2017 | $159M | $51M | $108M |
| 2016 | $148M | $41M | $107M |
| 2015 | $124M | $51M | $73M |
| 2014 | $79M | $25M | $54M |
| 2013 | $93M | $24M | $70M |
| 2012 | $77M | $25M | $52M |
| 2011 | $76M | $22M | $54M |

Source: [CompaniesByCap](https://companiesbycap.com/company/GMED)